Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

The Drugs industry as a whole closed the day down 1.0% versus the S&P 500, which was down 0.5%. Laggards within the Drugs industry included ImmuCell ( ICCC), down 4.5%, Oragenics ( OGEN), down 7.3%, Celator Pharmaceuticals ( CPXX), down 2.3%, Can Fite Biofarma ( CANF), down 2.4% and China Pharma ( CPHI), down 2.2%.

TheStreet Ratings Group would like to highlight 3 stocks that pushed the industry lower today:

Can Fite Biofarma ( CANF) is one of the companies that pushed the Drugs industry lower today. Can Fite Biofarma was down $0.10 (2.4%) to $4.08 on average volume. Throughout the day, 16,248 shares of Can Fite Biofarma exchanged hands as compared to its average daily volume of 21,100 shares. The stock ranged in price between $4.05-$4.20 after having opened the day at $4.20 as compared to the previous trading day's close of $4.18.

Can Fite Biofarma has a market cap of $33.9 million and is part of the health care sector. Shares are down 28.2% year-to-date as of the close of trading on Monday. Currently there is 1 analyst who rates Can Fite Biofarma a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

At the close, Celator Pharmaceuticals ( CPXX) was down $0.06 (2.3%) to $2.50 on light volume. Throughout the day, 5,800 shares of Celator Pharmaceuticals exchanged hands as compared to its average daily volume of 24,800 shares. The stock ranged in price between $2.50-$2.50 after having opened the day at $2.50 as compared to the previous trading day's close of $2.56.

Celator Pharmaceuticals has a market cap of $64.4 million and is part of the health care sector. Shares are down 24.1% year-to-date as of the close of trading on Monday. Currently there is 1 analyst who rates Celator Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Highlights from TheStreet Ratings analysis on CPXX go as follows:

You can view the full analysis from the report here: Celator Pharmaceuticals Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Oragenics ( OGEN) was another company that pushed the Drugs industry lower today. Oragenics was down $0.14 (7.3%) to $1.83 on light volume. Throughout the day, 9,319 shares of Oragenics exchanged hands as compared to its average daily volume of 31,000 shares. The stock ranged in price between $1.82-$1.98 after having opened the day at $1.98 as compared to the previous trading day's close of $1.97.

Oragenics, Inc. focuses on the discovery, development, and commercialization of various technologies associated with oral health, antibiotics, and other general health benefits. Oragenics has a market cap of $72.3 million and is part of the health care sector. Shares are down 28.8% year-to-date as of the close of trading on Monday. Currently there is 1 analyst who rates Oragenics a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Oragenics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income and generally disappointing historical performance in the stock itself.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Highlights from TheStreet Ratings analysis on OGEN go as follows:

  • The company, on the basis of change in net income from the same quarter one year ago, has significantly underperformed when compared to that of the S&P 500 and the Biotechnology industry. The net income has significantly decreased by 54.9% when compared to the same quarter one year ago, falling from -$1.99 million to -$3.08 million.
  • Despite any intermediate fluctuations, we have only bad news to report on this stock's performance over the last year: it has tumbled by 37.50%, worse than the S&P 500's performance. Consistent with the plunge in the stock price, the company's earnings per share are down 28.57% compared to the year-earlier quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
  • The company's current return on equity greatly increased when compared to its ROE from the same quarter one year prior. This is a signal of significant strength within the corporation. Compared to other companies in the Biotechnology industry and the overall market, ORAGENICS INC's return on equity significantly trails that of both the industry average and the S&P 500.
  • ORAGENICS INC's earnings per share declined by 28.6% in the most recent quarter compared to the same quarter a year ago. This company has reported somewhat volatile earnings recently. But, we feel it is poised for EPS growth in the coming year. During the past fiscal year, ORAGENICS INC continued to lose money by earning -$0.57 versus -$0.95 in the prior year. This year, the market expects an improvement in earnings (-$0.37 versus -$0.57).
  • The gross profit margin for ORAGENICS INC is currently very high, coming in at 84.60%. It has increased significantly from the same period last year. Regardless of the strong results of the gross profit margin, the net profit margin of -708.04% is in-line with the industry average.

You can view the full analysis from the report here: Oragenics Ratings Report

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.